Introduction {#s1}
============

Next-generation immune-based therapies are expected to facilitate the eradication of intractable pathogens, cancer and autoimmune diseases ([@bib25]). T cells play a critical role in such therapies by their ability to detect the presence of disease-specific antigens/peptides presented by major histocompatibility complex (MHC) molecules (human leukocyte antigen \[HLA\] molecules in humans). Under steady-state or pathological conditions, thousands of HLA class I-associated peptides of 8--12 amino acids in length are displayed on the surface of virtually all nucleated cells for scrutiny by CD8+ T cells. HLA class II-associated peptides are 10--25 amino acids in length and are normally found on the surface of specialized antigen-presenting cells including macrophages and dendritic cells for presentation to CD4+ T cells. Collectively, HLA class I and class II peptides are referred to as the immunopeptidome, also known as HLA ligandome/peptidome ([@bib5]; [@bib28]). The composition of the immunopeptidome in the human population is complicated by the presence of more than 3000 HLA alleles, resulting in a high diversity of peptide repertoires characterized by the presence of HLA allele-specific binding motifs ([@bib12]). To be successful in designing efficient immunotherapies against autoimmunity, cancer and infectious diseases, it is becoming increasingly important to comprehensively map the complexity of the human immunopeptidome and to gain a more quantitative understanding of its dynamics in various disease states.

Mass spectrometry (MS) has evolved as the method of choice for the exploration of the human immunopeptidome ([@bib20]; [@bib1]; [@bib15]). The largest HLA peptidomes reported to date using MS contain more than 10,000 class I or class II peptides ([@bib19]; [@bib3]; [@bib2]). Estimates from various analytical and cell-based techniques also indicate that individual peptides are expressed on average at 50 copies per cell with extremes ranging from 1 to 10,000 copies per cell ([@bib15]). Until recently, the most common strategy for the analysis of immunopeptidomes by MS has focused on the isolation of HLA-bound peptides by immunoaffinity chromatography and the collection of fragment ion spectra of selected peptides through automated MS operated in data-dependent acquisition (DDA) mode. Although DDA is a powerful strategy for exploring the peptidomic content of various cell and tissue types, it is not a reliable platform for solving problems that require the comparison of comprehensive, quantitative, and reproducible data sets across many samples or conditions. In fact, analyses of complex/unfractionated digests of cell lysate using DDA have shown that as many as 84% of peptides may remain unselected for fragmentation even though they are clearly detectable by the mass spectrometer ([@bib35]). Although the complexity of isolated HLA peptides is hardly comparable with that of cell lysate digests, as many as 20% of the selected HLA peptides can vary between replicate analyses of the same sample ([@bib16]) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). A second strategy, referred to as selected/multiple reaction monitoring (S/MRM), is a targeting MS technique capable of generating highly reproducible, quantitatively accurate and sensitive datasets ([@bib37]). S/MRM is, however, limited by its capacity to detect only tens to hundreds of peptides per sample injection and thus is not ideally suited to comprehensively quantify HLA peptidomes. To overcome this limitation, we recently introduced SWATH-MS, a new mass spectrometric technique that combines data-independent acquisition (DIA) with a targeted data extraction strategy ([@bib14]; [@bib39]). In DIA mode, all peptides in a sample are fragmented and the corresponding fragment ion spectra are acquired, resulting in a digital recording of the peptide sample. DIA is an unbiased MS technique and therefore represents a suitable strategy for efficiently generating consistent, reproducible and quantitatively accurate measurements of peptides across multiple samples ([@bib14]; [@bib6]; [@bib38]; [@bib39]; [@bib18]; [@bib32]; [@bib42]).

To extract quantitative information from digital SWATH-MS data, high-quality assay libraries are required. Such libraries contain retention-time and fragmentation information of the peptides to be targeted. Assay libraries are generated from native and/or synthetic peptides using a SWATH compatible mass spectrometer operated in DDA mode. To date, several generic SWATH assay libraries were generated for the analysis of proteomes in various species. These include *Mycobacterium tuberculosis* ([@bib42]), *Saccharomyces cerevisiae* ([@bib45]), and *Homo sapiens* ([@bib38]). Assay libraries were successfully employed to measure a limited number of MHC class I peptides by S/MRM in various contexts---that is, viral infection ([@bib8]), autoimmunity ([@bib40]) and cancer ([@bib17])---but have never been created for robust quantitative and high-throughput measurement of HLA-associated peptides by SWATH-MS.

For the SWATH-MS technology to meet its potential to support rapid advances in the design of next-generation vaccines and immunotherapies, comprehensive HLA peptide assay libraries have to be created and made readily available to basic and translational scientists. Generating such assay libraries could ultimately enable the fast and reproducible quantification of the entire repertoire of HLA peptides across many samples. Towards this end, we developed a workflow to (1) generate a pilot repository of HLA allele-specific peptide spectral and assay libraries, and to (2) analyze SWATH-MS HLA peptidomic data acquired from multiple international laboratories ([Figure 1](#fig1){ref-type="fig"}). In this study, libraries were created from natural and/or synthetic HLA class I and II peptides whereas analysis of SWATH-MS HLA peptidomic data focused mainly on naturally presented class I peptides.10.7554/eLife.07661.003Figure 1.General workflow for building HLA allele-specific peptide assay libraries and for analyzing SWATH-MS HLA peptidomic data.(Left panel) A community-based repository of HLA class I allele-specific peptide spectral and assay libraries was created and stored in the SWATHAtlas database. HLA typed-biological samples and synthetic HLA peptides were used to build the repository. Our workflow integrates (1) data-dependent acquisition (DDA) of HLA peptidomic data, (2) multiple open-source database search engines and statistical validation tools, (3) HLA allele annotation of the identified peptides, and (4) spectral and assay library generation tools. (Right panel) HLA peptidomic data from HLA-typed biological samples were acquired in data-independent acquisition (DIA) mode. The matching HLA class I allele-specific peptide assay libraries were combined and DIA data were analyzed using the OpenSWATH and the Skyline software.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.003](10.7554/eLife.07661.003)10.7554/eLife.07661.004Figure 1---source data 1.Comparative analysis of DDA and SWATH-MS for the identification of HLA class I peptides.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.004](10.7554/eLife.07661.004)10.7554/eLife.07661.005Figure 1---figure supplement 1.Reproducibility of DDA and SWATH-MS for the identification of HLA class I peptides.HLA class I peptides were isolated from JY^EBV+^ cells. Six technical replicates were consecutively injected in a TripleTOF 5600 MS. The Venn diagrams indicate the number of peptides identified in each analysis and the number of peptides shared between the runs. (**A**) Three datasets were acquired in DDA mode and the peptides were identified using the open source database search engines (1% peptide-level FDR). (**B**) Three datasets were acquired in SWATH mode and the peptides were identified using OpenSWATH and a combined HLA-A and -B peptide assay library (1% peptide-level FDR).**DOI:** [http://dx.doi.org/10.7554/eLife.07661.005](10.7554/eLife.07661.005)10.7554/eLife.07661.006Figure 1---figure supplement 2.Combining results of three open-source database search engines in immunopeptidomics using iProphet.(**A**) The HLA peptidome of fourteen PBMC samples were analyzed. Venn diagrams show the search results obtained from three database search engines (i.e., Comet, MS-GF+ and X!Tandem) at 5% peptide-level FDR. The search identifications were combined and statistically scored using PeptideProphet and iProphet within the Trans-Proteomic Pipeline (TPP). Following annotation of all identified peptides to their respective HLA allele, all nonannotated peptides were removed from the iProphet combined search result and a corrected false discovery rate (cFDR) was manually calculated based on the target-decoy approach. cFDR is indicated for each PBMC sample. At peptide-level FDR 1%, the cFDR was estimated on average at 0.5%. At peptide-level FDR 5%, the cFDR was estimated at 2.5%. (**B**) The table shows the number of HLA class I peptides identified from the iProphet combined search results that were used to build the spectral libraries. The sum of peptides identified by the three search engines (Union) as well as the number of overlapping peptides (Intersection) for each venn diagram/sample is also indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.006](10.7554/eLife.07661.006)10.7554/eLife.07661.007Figure 1---figure supplement 3.Combining both open-source and commercial database search engines in immunopeptidomics.Analysis of PBMC\#2 is shown here as an example. (**A**) Comparison of search results obtained from multiple search engines and for different class I HLA alleles at 1% and 5% peptide-level FDR. Performance of two commercial search engines (Mascot+Percolator or Mascot alone, and PEAKS) is also shown here for comparison. (**B**) Venn diagram showing the performance of the search engines at 5% pep-level FDR (2.5% cFDR).**DOI:** [http://dx.doi.org/10.7554/eLife.07661.007](10.7554/eLife.07661.007)

Results and discussion {#s2}
======================

Large-scale DDA-based identification of immunoaffinity purified HLA class I peptides is supported by several software tools (e.g., MaxQuant, Perseus or X-PRESIDENT) and results in thousands of unclassified peptides of various lengths. Since large HLA peptidomic datasets are generated at an increasing pace, additional computational frameworks facilitating the HLA annotation and storage of such datasets need to be developed. Here, we first created a computational workflow to support the identification, classification/annotation, visualization and storage of HLA peptidomic data in an allele-dependent manner. The software tools described in the section below enable (1) systematic annotation of peptides to their respective HLA allele, (2) visualization of HLA peptidomic datasets, and (3) generation of HLA class I allele-specific peptide spectral libraries, which can be converted into high quality assay libraries for the processing of SWATH-data ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"} and [Supplementary file 1](#SD8-data){ref-type="supplementary-material"}).10.7554/eLife.07661.008Figure 2.Content and analysis of the pilot repository.(**A**) HLA peptides were isolated by immunoaffinity chromatography and were annotated to their respective HLA alleles following DDA mass spectrometry. (**B**) Heat map visualization of HLA class I peptides identified from 20 HLA-typed biological samples. HLA-A and -B alleles are indicated for each sample. (**C**) 35,812 distinct class I and class II HLA peptides were identified, annotated, and used to build 32 and 11 HLA allele-specific peptide spectral and SWATH assay libraries, respectively. (**D**) The distribution curve shows that 95% of the HLA-B07-annotated peptides were predicted to bind the HLA molecule with an IC50 below 531 nM. Inner pie chart: we assessed the predicted HLA binding affinity of all peptides contained in individual source proteins. The pie chart shows that 92% of naturally presented HLA-B07 peptides were ranked in the top 1% (blue) of predicted peptides (see also [Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.07661.008](10.7554/eLife.07661.008)10.7554/eLife.07661.009Figure 2---source data 1.Sources of HLA peptides used in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.009](10.7554/eLife.07661.009)10.7554/eLife.07661.010Figure 2---source data 2.Annotation of HLA peptides.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.010](10.7554/eLife.07661.010)10.7554/eLife.07661.011Figure 2---source data 3.List of eluted HLA class I peptides that were identified at 1% and 5% peptide-level FDR.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.011](10.7554/eLife.07661.011)10.7554/eLife.07661.012Figure 2---source data 4.HLA class I allele-specific peptide spectral libraries stored in PeptideAtlas.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.012](10.7554/eLife.07661.012)10.7554/eLife.07661.013Figure 2---source data 5.HLA class I and II allele-specific peptide assay libraries stored in the SWATHAtlas database.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.013](10.7554/eLife.07661.013)10.7554/eLife.07661.014Figure 2---figure supplement 1.Automated NetMHC-based method for annotating and visualizing HLA allele-specific peptides.PBMC\#2 was typed positive for HLA-A02, -A03, -B35, -B39, and is shown here as a representative sample. (**A**) The stand-alone software package of the HLA binding prediction algorithm NetMHC 3.4 was used to predict the binding affinity of all identified peptides to HLA-A02, -A03, -B35 and -B39 (four peptides are shown for simplicity). For each peptide, an annotation score was calculated by dividing the second lowest IC~50~ value (second best predicted allele) by the lowest IC~50~ value (best predicted allele). Peptides with a score ≥3 were annotated to the HLA allele predicted to bind best. Peptides with a score below 3 were considered as non-annotated. Non-annotated peptides were curated in the output files in [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"} and correspond to 1) non-HLA peptides/contaminants, 2) peptides predicted to strongly bind more than one HLA allele (supertype peptides), 3) peptides predicted to bind HLA-C alleles, 4) exceptional HLA peptides with no known binding motifs. Annotation scores of all eluted peptides are shown in [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}. Additional information is provided in [Supplementary file 1](#SD8-data){ref-type="supplementary-material"}. (**B**) Curves showing the distribution of the predicted HLA binding affinities for all HLA-A03-annotated peptides with a score ≥3. Overall, 91% of all HLA-A03-annotated peptides are predicted to have a binding affinity below 500 nM for the HLA-A03 molecule (see also [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} and [Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). The same peptides are predicted to be non-binders for the other alleles -- i.e., HLA-A02, -B35 and -B39. (**C**) Heat map visualization following clustering of predicted HLA binding affinity values. The white box highlights HLA-A03-annotated peptides. The four peptides in the table in (a) are indicated by arrows and their respective predicted binding affinity for the HLA-A03 molecule is indicated in parenthesis.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.014](10.7554/eLife.07661.014)10.7554/eLife.07661.015Figure 2---figure supplement 2.Identification of HLA class I allele-specific peptides by DDA.(**A**) Number of distinct HLA class I allele-specific peptides identified using an Orbitrap-XL and a 5600 TripleTOF at peptide-level FDR 5%. (**B**) Logo showing the profile motif for peptides presented by different HLA-A and -B alleles. Profile motifs were created by using all annotated HLA class I peptides in this study and the sequence logo generator WebLogo.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.015](10.7554/eLife.07661.015)10.7554/eLife.07661.016Figure 2---figure supplement 3.Generation of assay libraries from a large collection of synthetic HLA class II peptides.(**A**) Workflow to generate an assay library from synthetic peptides. A total of 20,176 predicted peptides (with a range of 2 to 10 per ORF, and an average of 5), were synthesized and arranged into 23 peptide pools of \~900 peptides (Lindestam Arlehamn et al., PLoS Pathog, 2013). Spiked-in reference iRT peptides were used and the pools of synthetic peptides were analyzed in DDA mode using a 5600 Triple-TOF and an Orbitrap ELITE (CID and HCD fragmentation). The identified peptides were then processed through our computational pipeline to generate the assay library. (**B**) Venn diagram showing the overlap between peptides identified by the 5600 Triple-TOF and by the ELITE (CID and HCD fragmentation methods). Number of peptides identified is indicated in parenthesis. (**C**) Histogram showing the distribution of the precursor charge state.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.016](10.7554/eLife.07661.016)10.7554/eLife.07661.017Figure 2---figure supplement 4.Distribution curves of peptide binding affinities for different HLA-A and -B alleles (1% peptide-level FDR; 0.5% cFDR).The predicted IC~50~ values of the annotated peptides in [Figure 2---source data 3](#SD4-data){ref-type="supplementary-material"} were used to generate the distribution curves (blue line). The proportion of peptides with a predicted affinity lower than the established 500nM threshold (grey) is indicated for individual HLA alleles. The plots also indicate that 95% of the annotated peptides (green) are predicted to bind their respective HLA molecules with an IC50 ranging from 72 nM (HLA-A01) to 5682 nM (HLA-B51).**DOI:** [http://dx.doi.org/10.7554/eLife.07661.017](10.7554/eLife.07661.017)10.7554/eLife.07661.018Figure 2---figure supplement 5.Distribution curves of peptide binding affinities for different HLA-A and -B alleles (5% peptide-level FDR; 2.5% cFDR).The predicted IC~50~ values of the annotated peptides in [Figure 2---source data 3](#SD4-data){ref-type="supplementary-material"} were used to generate the distribution curves (blue line). The proportion of peptides with a predicted affinity lower than the established 500nM threshold (grey) is indicated for individual HLA alleles. The plots also indicate that 95% of the annotated peptides (green) are predicted to bind their respective HLA molecules with an IC50 ranging from 388 nM (HLA-A01) to 5761 nM (HLA-B51).**DOI:** [http://dx.doi.org/10.7554/eLife.07661.018](10.7554/eLife.07661.018)10.7554/eLife.07661.019Figure 2---figure supplement 6.Binding scores of naturally presented HLA-A and -B peptides contained in individual source proteins.We assessed the predicted HLA binding affinity of all peptides contained in individual source proteins. The pie chart shows the proportion of naturally presented peptides isolated by immunoaffinity chromatography that ranked in the top 1% (blue), top 5% (red), top 10% (yellow), or below the 90th percentile of peptides (pale blue).**DOI:** [http://dx.doi.org/10.7554/eLife.07661.019](10.7554/eLife.07661.019)

To test our workflow, the generated data and computational resources, we first assessed the feasibility of generating HLA class I allele-specific peptide spectral libraries from a panel of fourteen PBMC samples (PBMC \#1--14) expressing different combinations of HLA class I alleles. HLA class I-bound peptides were isolated from HLA-typed PBMC\'s by immunoaffinity chromatography and analyzed by DDA on an Orbitrap-XL mass spectrometer ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}). Peptides were identified using multiple open-source database search engines. The search identifications were combined and statistically scored using PeptideProphet and iProphet within the Trans-Proteomic Pipeline (TPP) as shown previously ([Figure 1](#fig1){ref-type="fig"}) ([@bib46], [@bib47]). We next annotated the identified peptides to their respective HLA allele. Previously, HLA binding prediction algorithms such as SYFPETHI, NetMHC and SMM were used for manual or semi-automated annotation of HLA peptides ([@bib13]; [@bib4]; [@bib16]). Here, we designed a fully automated annotation strategy integrating the stand-alone software package of the HLA binding prediction algorithm NetMHC 3.4 with a set of in-house software tools ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The in-house software tools enable an automated, consistent and effective annotation of the majority of the identified peptides to their respective HLA allele ([Supplementary file 1](#SD8-data){ref-type="supplementary-material"}). Briefly, each identified peptide was given a predicted HLA binding affinity (IC~50~) for each of the HLA alleles expressed in the corresponding healthy donor. An HLA annotation score was then computed for each individual peptide by dividing its second best IC~50~ value (i.e., the second best predicted allele) by its best IC~50~ value (i.e., the best predicted allele). The higher this annotation score was, the higher the probability was for the peptide to be correctly annotated to a specific HLA allele. As an example, in PMBC\#2, an annotation score of 77 was computed for the KLEEQARAK peptide by dividing 21,400 nM (second best IC~50~ value predicted for HLA-B39) by 278 nM (best IC~50~ value predicted for HLA-A03) ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Peptides with an HLA annotation score ≥3 (selected cutoff value; see 'Materials and methods' and [Supplementary file 1](#SD8-data){ref-type="supplementary-material"}) were systematically annotated to the allele predicted to bind best (e.g., HLA-A03 for the KLEEQARAK peptide). Using this scoring strategy, ∼80% of all identified 8--12-mers were annotated to a specific HLA-A or -B allele ([Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}). HLA-A and -B alleles were prioritized due to the high reliability of the NetMHC 3.4 predictor for a broad diversity of HLA-A and -B alleles as well as for their high expression levels ([@bib24]; [@bib2]; [@bib49]). Peptides with an annotation score below 3 were considered as non-annotated in this study and were discarded for the process of building the HLA allele-specific peptide spectral libraries. Tables including scored peptides were then used to generate heat maps and visualize HLA-A and -B peptidomes of PBMC\'s as described ([Figure 2B](#fig2){ref-type="fig"} and [Supplementary file 1](#SD8-data){ref-type="supplementary-material"}). Of note, allele-supertype peptides (i.e., peptides predicted to strongly bind more than one allele with an IC~50~ below 500 nM) were curated in the output files but were not visualized on the heat maps in this study. A corrected false discovery rate (cFDR) was estimated for each PBMC sample following removal of all non-annotated contaminant peptides ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), resulting in a total of 4153 (peptide-level FDR 1%; average cFDR 0.5%) or 7921 (peptide-level FDR 5%; average cFDR 2.5%) distinct annotated peptides distributed across eighteen HLA class I alleles ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"} and [Figure 2---source data 3](#SD4-data){ref-type="supplementary-material"}). All annotated peptides identified from the 14 PBMC samples were then used in SpectraST ([@bib30]) to build the HLA class I allele-specific peptide spectral libraries ('Materials and methods'). The same procedure was applied to peptides identified from JY^EBV+^ and C1R cells. Notably, endogenous HLA-C04 peptides were recently shown to be significantly expressed on the surface of C1R cells ([@bib41]) and were therefore considered in this study. In total, 3528 HLA-A peptides, 4208 HLA-B peptides and 205 HLA-C04 peptides were recorded in the spectral libraries, which were then stored in the public PeptideAtlas database ([Figure 2---source data 4](#SD5-data){ref-type="supplementary-material"}). In summary, we generated a computational workflow to effectively annotate and visualize HLA peptidomic data, which were finally converted and stored into HLA allele-specific peptide spectral libraries consisting of consensus fragment ion spectra. This strategy could be further refined to collect, store and share HLA peptidomic information obtained from various cell lines and from larger cohorts of donors. Importantly, this computational approach can be broadly applied to generate SWATH-compatible assay libraries as described below.

Libraries of consensus fragment ion spectra can be converted into high quality assays for high-throughput targeted analysis of SWATH-MS data, an emerging approach for reproducible, consistent and accurate quantitative measurements of peptides ([@bib14]; [@bib6]; [@bib38]; [@bib39]; [@bib18]; [@bib32]; [@bib45]; [@bib42]). Here, we aimed at initiating a worldwide community-based effort to generate pilot HLA allele-specific peptide assay libraries that could be further used for the analysis of SWATH-MS HLA peptidomic data. Naturally presented and/or synthetic HLA class I and class II peptides were provided from six independent laboratories and were analyzed using four distinct TripleTOF 5600 MS instruments operated in DDA acquisition mode in four different international institutions. Naturally presented HLA class I peptides from JY^EBV+^ (HLA-A02 and -B07), PBMC (HLA-A03, -A26, -B51 and -B57), and Jurkat (HLA-A03, -B07 and -B35) cells were isolated by immunoaffinity chromatography ([Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}). Natural class I peptides from three C1R cell lines---stably expressing HLA-C04 as well as HLA-B27, -B39 or -B40 molecules---were also isolated using the same procedure. Synthetic EBV-derived peptides known to bind HLA-A02 or -B07 were also used to build the libraries ([Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}). All laboratories used the spiked-in landmark iRT peptides for retention time normalization ([@bib11]). The DDA data generated by the different groups were shared and pipelined through the computational workflow described above, resulting in the identification of 7668 (peptide-level FDR 1%; average cFDR 0.5%) or 11,275 (peptide-level FDR 5%; average cFDR 2.5%) distinct HLA class I peptides distributed across eleven different HLA class I alleles ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"} and [Figure 2---source data 3](#SD4-data){ref-type="supplementary-material"}). To properly assess the efficiency of generating HLA peptide assay libraries from synthetic peptides, a large collection of 20,176 synthetic HLA class II peptides was analyzed by DDA using different mass spectrometers and fragmentation methods ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} and [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}). Our results show that a total of 15,875 peptides (∼79%) were identified ([Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}). A large collection of synthetic HLA class I peptides was not available but could be used in the future to extend the contents of the present class I libraries derived from native peptides. All identified peptides were used to build the HLA allele-specific peptide assay libraries ('Materials and methods'). To date, the pilot libraries contain a total of 223,735 transitions for 26,857 unique peptides and were stored by class and allele in the SWATHAtlas database ([Figure 2---source data 5](#SD6-data){ref-type="supplementary-material"} and [http://www.swathatlas.org](http://www.swathatlas.org/)). By using the automated HLA peptide annotation method described above, we observed that similar binding affinities were predicted for HLA class I peptides identified at peptide-level FDR 1% and peptide-level FDR 5% ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} and [Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}), suggesting that a large fraction of true positives were excluded at peptide-level FDR 1%. Our data also show that 95% of the annotated class I peptides in this study were predicted to bind their respective HLA molecules with an IC~50~ ranging from 72 nM (for HLA-A01) to 5682 nM (for HLA-B51) at peptide-level FDR 1% ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). Similar results were obtained at peptide-level FDR 5% ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). This result supports a recent study indicating that HLA class I alleles are associated with peptide-binding repertoires of different affinity ([@bib36]). Altogether, we demonstrated the feasibility of collecting DDA data from multiple international laboratories to generate standardized HLA allele-specific peptide assay libraries. We anticipate this global effort as a first step towards the development of a standardized Pan-human HLA peptide assay library, which could be used to rapidly and reproducibly quantify the entire repertoire of peptides presented by HLA molecules using SWATH-MS.

SWATH-MS is emerging as a robust next-generation proteomics technique for efficiently generating reproducible, consistent and quantitatively accurate measurements of peptides across multiple samples ([@bib14]; [@bib6]; [@bib38]; [@bib39]; [@bib18]; [@bib32]; [@bib45]; [@bib42]). To promote the worldwide development of SWATH-based MS platforms towards robust quantitative measurements of HLA peptidomes, we assessed whether the HLA allele-specific assay libraries described above could be used to extract quantitative information from digital SWATH maps acquired by different laboratories. Importantly, four independent laboratories generated their own digital SWATH maps using TripleTOF 5600 MS operated in DIA acquisition mode. Naturally presented HLA class I peptides were isolated from the cell types mentioned above (i.e., JY^EBV+^, Jurkat, PBMC and C1R). Precursors in the range of 400--1200 Th were divided into 32 SWATH windows of 25 Da ([@bib14]). All ionized peptide precursors in this mass range were fragmented, generating comprehensive and quantitative digital fragment ion maps. The HLA peptidome of JY^EBV+^ cells was analyzed using the OpenSWATH ([@bib39]) software tool and a combined assay library containing 22,206 transitions for 1507 HLA-A02 and 2194 HLA-B07 peptides---the two dominant HLA alleles expressed on these cells. At an estimated peptide-level FDR of 1% (m-score \< 0.01), a total of 3150 unique HLA class I peptides were identified from the digital SWATH map ([Figure 3A,B,C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 7](#fig3s7){ref-type="fig"} and [Figure 3---source data 1](#SD7-data){ref-type="supplementary-material"}). Notably, assays generated from the synthetic EBV-related class I peptides enabled the identification of one EBV-derived HLA-A02 peptide ([Figure 3C](#fig3){ref-type="fig"}), thereby demonstrating that building high-quality assay libraries from synthetic class I peptides of pathogen origin could be useful for the identification of non-self HLA-bound peptides by SWATH-MS. To analyze self-HLA peptides isolated from PBMC (HLA-A03, -A26, -B51 and -B57), Jurkat (HLA-A03, B07 and -B35), C1R-B27 (HLA-B27) and C1R-B40 (HLA-B40) cells, the matching HLA class I allele-specific peptide assay libraries were combined accordingly using SpectraST and then processed in the OpenSWATH software. High-throughput targeted analysis from these four additional peptidomic datasets indicated that ∼81% of HLA class I peptides present in an assay library could be extracted from a quantitative digital SWATH map in a cell type-independent manner (peptide-level FDR 1%) ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}, [Figure 3---figure supplements 2--6](#fig3s2 fig3s3 fig3s4 fig3s5 fig3s6){ref-type="fig"} and [Figure 3---source data 1](#SD7-data){ref-type="supplementary-material"}). We next optimized the SWATH acquisition conditions according to the size distribution of HLA class I peptides. Most class I peptide precursors (∼98%) fall within the range of 400--700 Th and were divided in 30 SWATH windows of 10 Da width each. Using SWATH data generated from JY^EBV+^ cells, we found that narrowing the size of the windows by 2.5-fold resulted in a ∼13% fold-increase in the identification of class I peptides ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The *R*^*2*^ value for SWATH-MS quantification was 0.979 from two technical replicates ([Figure 3D](#fig3){ref-type="fig"}). In accordance with previous studies, we also observed that the dynamic range of peptides quantified in different cell types using SWATH-MS, based on their signal intensity, was about 3-4 orders of magnitude ([Figure 3E](#fig3){ref-type="fig"}) ([@bib19]; [@bib2]). Altogether, we demonstrate the feasibility of an international effort to build standardized HLA allele-specific peptide assay libraries, which were used to extract quantitative information from digital SWATH maps acquired in different sites. We therefore provide a proof of concept that acquisition of SWATH-MS HLA peptidomic data may enable robust analysis of the human immunopeptidome on a global scale.10.7554/eLife.07661.020Figure 3.High-throughput targeted analysis of HLA peptidomic data by SWATH-MS.(**A**) SWATH-MS coordinates of two HLA class I allele-specific assay libraries (HLA-A02 and -B07) were combined to extract SWATH data generated from the HLA peptidome of JY^EBV+^ cells. Sixteen summed transition groups are shown here for simplicity. (**B**, **C**) Visualization of two extracted SWATH transition groups corresponding to the self-HLA-A02 peptide, KILPTLEAV and the non-self HLA-A02 EBV peptide, YVLDHLIVV. (**D**) Reproducibility of intensity measurements for technical replicates. (**E**) Dynamic range of transition group intensities following targeted analysis of SWATH-MS HLA peptidomic data generated from various cell types expressing different combinations of HLA alleles. SWATH/DIA data were acquired in four independent international laboratories.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.020](10.7554/eLife.07661.020)10.7554/eLife.07661.021Figure 3---source data 1.OpenSWATH analysis.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.021](10.7554/eLife.07661.021)10.7554/eLife.07661.022Figure 3---figure supplement 1.OpenSWATH analysis of HLA peptidomic data.(**A**) HLA class I peptides isolated from JY cells were acquired in SWATH/DIA mode using windows of 10 Da (blue) or 25 Da (red) width each. The graph shows the proportion of peptides that were confidently extracted (FDR \< 0.01) using OpenSWATH from a merged (A02+B07) or unmerged (A02 or B07) HLA allele-specific assay library. (**B**) pyProphet statistical analysis from a JY HLA class I peptide extract. The histogram plots show the distribution of decoy and target transition groups according to their discriminant score (dscore) determined by the pyProphet software. (**C**) HLA class I peptides were isolated form various cell types and analyzed by SWATH-MS using windows of 25 Da width each. The histogram shows the number of HLA peptides that were confidently extracted (FDR \< 0.01) using OpenSWATH from different HLA allele-specific assay library.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.022](10.7554/eLife.07661.022)10.7554/eLife.07661.023Figure 3---figure supplement 2.OpenSWATH analysis and PyProphet statistics of HLA peptidomic data acquired at ETH Zurich, Switzerland.HLA-A02 and HLA-B07 peptides were isolated from JY cells. Graphs showing ROC, d_score performance and d-score distributions were generated automatically using the iPortal workflow.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.023](10.7554/eLife.07661.023)10.7554/eLife.07661.024Figure 3---figure supplement 3.OpenSWATH analysis and PyProphet statistics of HLA peptidomic data acquired at ETH Zurich, Switzerland.HLA-A03, -A26, -B51 and -B57 peptides were isolated from PBMCs. Graphs showing ROC, d_score performance and d-score distributions were generated automatically using the iPortal workflow.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.024](10.7554/eLife.07661.024)10.7554/eLife.07661.025Figure 3---figure supplement 4.OpenSWATH analysis and PyProphet statistics of HLA peptidomic data acquired at University of Oxford, UK.HLA-A03, -B07 and -B35 peptides were isolated from Jurkat cells. Graphs showing ROC, d_score performance and d-score distributions were generated automatically using the iPortal workflow.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.025](10.7554/eLife.07661.025)10.7554/eLife.07661.026Figure 3---figure supplement 5.OpenSWATH analysis and PyProphet statistics of HLA peptidomic data acquired at Monash University, Australia.HLA-B27 peptides were isolated from C1R cells. Graphs showing ROC, d_score performance and d-score distributions were generated automatically using the iPortal workflow.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.026](10.7554/eLife.07661.026)10.7554/eLife.07661.027Figure 3---figure supplement 6.OpenSWATH analysis and PyProphet statistics of HLA peptidomic data acquired at Centro National de Biotechnologia, Madrid, Spain.HLA-B40 peptides were isolated from C1R cells. Graphs showing ROC, d_score performance and d-score distributions were generated automatically using the iPortal workflow.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.027](10.7554/eLife.07661.027)10.7554/eLife.07661.028Figure 3---figure supplement 7.Visualization and analysis of SWATH-MS HLA peptidomic data in Skyline.Skyline is a free open-source software for targeted data analysis of various types of peptidomic data. It specifically facilitates manual and automated analysis of SWATH data and other data-independently acquired MS data using assay libraries. The software itself can be downloaded from the website: <http://skyline.maccosslab.org>. (**A**) Skyline-daily or Skyline v2.6 was used to import HLA peptide SWATH assay libraries, and to import, extract, and visualize SWATH HLA peptidomic data. (**B**) The 'Advanced Peak Picking Models' was used to work with decoy transition groups and for large-scale, automated SWATH data analysis. For more information, see [@bib43].**DOI:** [http://dx.doi.org/10.7554/eLife.07661.028](10.7554/eLife.07661.028)

To further establish the robustness of SWATH-MS for the measurement of HLA-associated peptides, we tested whether the JY^EBV+^ HLA peptidome could be reproducibly detected across multiple MS injections. For this purpose, we prepared a sample of class I peptides by immunoaffinity purification from JY^EBV+^ cells and we acquired three datasets in SWATH mode. The datasets were analyzed using OpenSWATH and a combined HLA-A02 and -B07 peptide assay library as described above. At an estimated peptide-level FDR of 1%, a total of 2933 unique HLA class I peptides were identified by SWATH-MS and 2832 peptides (97%) were found in all the SWATH analyses ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). We then conducted a comparative analysis by acquiring three additional datasets in DDA mode from the same sample of class I peptides using the same chromatographic conditions. In total, 3153 HLA-A and -B peptides were identified at 1% peptide-level FDR and 1261 peptides (40%) were found in all the DDA analyses ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Thus, the SWATH method clearly outperformed the DDA approach for the reproducible identification of JY^EBV+^ HLA class I peptides across several technical replicates. Overall, our results indicate that SWATH-MS has the capability of detecting large numbers of HLA peptides across multiple injections at a high degree of reproducibility. By providing a community resource for the continuous expansion of the library contents and by improving the performance of the OpenSWATH software, it can be expected that additional HLA peptides---including cryptic and mutant peptides---will be reproducibly identified and quantified from the same digital SWATH maps in the future.

The life sciences community greatly benefits from robust technologies such as microarrays and RNA-seq. Similarly, robust generation and analysis of quantitative digital maps of HLA peptidomes is expected to have important implications in basic and translational research as these will allow research groups to accurately investigate the dynamics of immunopeptidomes in various immune-related diseases such as autoimmunity, infectious diseases and cancers. For instance, reproducible digital mapping of tumor-specific mutant HLA peptides during cancer progression will facilitate stratification of patients who might best benefit from innovative immunotherapeutic interventions ([@bib17]; [@bib48]; [@bib44]). The workflow and the computational and data resources presented in this community-based study is a first step towards highly reproducible and quantitative MS-based measurements of HLA peptidomes across many samples and could therefore be greatly beneficial in the design of personalized immune-based therapies. Moreover, the storage of HLA peptide spectral and assay libraries by class and allele in the SWATHAtlas database provides an initial framework to collect, organize and share HLA peptidomic data, thereby supporting the recently proposed Human Immunopeptidome and Vaccines Projects ([@bib1]; [@bib26]).

Materials and methods {#s3}
=====================

Blood samples, cell lines and synthetic peptides {#s3-1}
------------------------------------------------

PBMCs from healthy donors were isolated by density gradient centrifugation. Informed consent was obtained in accordance with the Declaration of Helsinki protocol. HLA typing was carried out by the Department of Hematology and Oncology, Tübingen, Germany. PBMCs were stored at −80°C until further use. JY^EBV+^, Jurkat and C1R cells were cultured in RPMI supplemented with 10% fetal bovine serum, 50 IU/ml penicillin, and 50ug/ml streptomycin (Invitrogen, Life Technologies Europe BV, Zug, Switzerland). C1R cells were stably transfected with -B2705, -B3901 and -B4002 constructs, as described previously ([@bib34]; [@bib40]). The EBV peptide was synthesized by Thermo Fischer Scientific (Ulm, Germany). The collection of 20,176 MTB peptides was synthesized by Mimotopes (Victoria, Australia) as described ([@bib31]).

Isolation of HLA peptides {#s3-2}
-------------------------

HLA class I peptide complexes were isolated by standard immunoaffinity purification as described previously using the pan-HLA class I-specific mAb W6/32 ([@bib20]; [@bib8]; [@bib27]; [@bib34]).

RT normalization peptides {#s3-3}
-------------------------

For the RT normalization and analysis, the peptides from the iRT Kit (Biognosys AG, Schlieren, Switzerland) were added to samples (see [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}) prior to MS injection according to vendor instructions ([@bib11]).

DDA mass spectrometry {#s3-4}
---------------------

### AB SCIEX TripleTOF 5600^*+*^ {#s3-4-1}

Both naturally presented and synthetic HLA peptides were analyzed using a TripleTOF system (see [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}) as described before ([@bib14]; [@bib39]). Samples were analyzed on an Eksigent nanoLC (AS-2/1Dplus or AS-2/2Dplus) system coupled with a SWATH-MS-enabled AB SCIEX TripleTOF 5600^+^ System. The HPLC solvent system consisted of buffer A (2% acetonitrile and 0.1% formic acid in water) and buffer B (2% water with 0.1% formic acid in acetonitrile). The samples were separated in a 75 µm-diameter PicoTip emitter (New Objective, Woburn, MA) packed with 20 cm of Magic 3 µm, 200 Å C18 AQ material (Bischoff Chromatography, Leonberg, Germany). The loaded material was eluted from the column at a flow rate of 300 nl/min with the following gradient: linear 2--35% B over 120 min, linear 35--90% B for 1 min, isocratic 90% B for 4 min, linear 90--2% B for 1 min and isocratic 2% solvent B for 9 min. The mass spectrometer was operated in DDA top20 mode, with 500 and 150 ms acquisition time for the MS1 and MS2 scans respectively, and 20 s dynamic exclusion. Rolling collision energy with a collision energy spread of 15 eV was used for fragmentation.

### Thermo scientific orbitrap ELITE {#s3-4-2}

Mtb synthetic peptides were analyzed on an Eksigent LC system coupled to an LTQ-Orbitrap ELITE mass spectrometer. Peptides were separated on a custom C18 reversed phase column (150 mm i.d. × 100 mm, Jupiter Proteo 4 mm, Phenomenex) using a flow rate of 600 nl min^−1^ and a linear gradient of 3--60% aqueous ACN (0.2% formic acid) in 120 min. Full mass spectra were acquired with the Orbitrap analyser operated at a resolving power of 30,000 (at m/z 400). Mass calibration used an internal lock mass (protonated (Si(CH3)2O))6; m/z 445.120029) and mass accuracy of peptide measurements was within 5 p.p.m. MS/MS spectra were acquired in CID and HCD mode with a normalized collision energy of 35%. Up to ten precursor ions were accumulated to a target value of 50,000 with a maximum injection time of 300 ms and fragment ions were transferred to the Orbitrap analyser operating at a resolution of 15,000 at m/z 400.

### Thermo scientific orbitrap XL {#s3-4-3}

Naturally presented HLA class I peptides from several PBMC samples (see [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}) were also analyzed by reversed-phase liquid chromatography (nano-UHPLC, UltiMate 3000 RSLCnano; Thermo Fisher, Waltham, MA, USA) coupled with an LTQ Orbitrap XL hybrid mass spectrometer. Samples were analyzed in five technical replicates. Sample volumes of 5 μl (sample shares of 20%) were injected onto a 75 μm × 2 cm trapping column (Acclaim PepMap RSLC; Thermo Fisher) at 4 μl/min for 5.75 min. Peptide separation was subsequently performed at 50°C and a flow rate of 175 nl/min on a 50 μm × 50 cm separation column (Acclaim PepMap RSLC; Thermo Fisher) applying a gradient ranging from 2.4 to 32.0% of acetonitrile over the course of 140 min. Eluting peptides were ionized by nanospray ionization and analyzed in the mass spectrometer implementing a top five CID method generating fragment spectra for the five most abundant precursor ions in the survey scans. Resolution was set to 60,000. For HLA class I ligands, the mass range was limited to 400--650 m/z with charge states 2 and 3 permitted for fragmentation.

Database search engines and statistical validation {#s3-5}
--------------------------------------------------

All raw instrument data were centroided and processed as described previously ([@bib6]; [@bib38]). The datasets were searched individually using X!tandem ([@bib7]), MS-GF+ ([@bib23]) and Comet ([@bib10]) against the full non-redundant, canonical human genome as annotated by the UniProtKB/Swiss-Prot (2014_02) with 20,270 ORFs and appended iRT peptide and decoy sequence. Oxidation (M) was the only variable modification. Parent mass error was set to ±5 p.p.m., fragment mass error was set to ±0.5 Da. The search identifications were then combined and statistically scored using PeptideProphet ([@bib21]) and iProphet ([@bib46]) within the TPP (4.7.0) ([@bib22]). All peptides with an iProbability/iProphet score above 0.7 were exported in Excel. Assumed charges were also exported, as this information is needed in SpectraST. Length considered was 8--12 residues for class I HLA peptides. FDR was manually estimated based on the target-decoy approach ([@bib9]). Peptides (1% and 5% peptide-level FDR) were then exported to a .txt file for annotation to their respective HLA allele.

HLA allele annotation {#s3-6}
---------------------

Annotation of the identified peptides (1% and 5% peptide-level FDR) to their respective HLA allele was performed automatically by integrating the stand-alone software package of NetMHC 3.4 ([@bib33]) with our in-house software tools ([Supplementary file 1](#SD8-data){ref-type="supplementary-material"} and [Source code 1](#SD9-data){ref-type="supplementary-material"}). An HLA annotation score was computed by the software tools for individual peptides ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). A predefined cutoff score of 3 was then used to annotate each peptide to their respective HLA allele. A cutoff value of 3 was selected because \>90% of the identified peptides with an annotation score above 3 have a predicted IC~50~ below 1000 nM. FDR was corrected from the list of annotated HLA peptides based on the target-decoy approach ([@bib9]). The software tools were used to process and visualize the peptidomic datasets. The final lists of HLA-allele specific peptides were exported into a .txt file and used in SpectraST for library generation.

Generation of HLA allele-specific peptide spectral and assay libraries {#s3-7}
----------------------------------------------------------------------

This section was adapted from [@bib43]. The parameters below were used for Spectrast ([@bib30]). Exact meaning of each parameter can be found in the following link: <http://tools.proteomecenter.org/wiki/index.php?title=Software:SpectraST>. Spectrast was used in library generation mode with CID-QTOF settings (-cICID-QTOF) for the Triple-TOF 5600^+^ or CID (default) settings for the Orbitrap-XL and Orbitrap-ELITE. Retention times were normalized against the iRT Kit peptide sequences (-c_IRTiRT.txt -c_IRR). Only HLA-allele specific peptide ions were included for library generation (-cT):

spectrast -cNSpecLib_celltype_allele_fdr_iRT -cICID-QTOF -cTReference_celltype_allele_fdr.txt -cP0.7 -c_IRTiRT.txt -c_IRR iprophet.pep.xml

A consensus library was then generated:

spectrast -cNSpecLib_cons_celltype_allele_fdr_iRT -cICID-QTOF -cAC SpecLib_celltype_allele_fdr_iRT.splib

HLA-allele specific consensus libraries were merged:

spectrast -cNSpecLib_cons_celltype_alleles_fdr_iRT -cJU -cAC SpecLib_celltype_allele1_fdr_iRT.splib SpecLib_celltype_allele2_fdr_iRT.splib SpecLib_celltype_allele3_fdr_iRT.splib SpecLib_celltype_allele4_fdr_iRT.splib

The script spectrast2tsv.py (msproteomicstools 0.2.2; <https://pypi.python.org/pypi/msproteomicstools>) was then used to generate the HLA-allele specific peptide assay library with the following recommended settings:

spectrast2tsv.py -l 350,2000 -s b,y -x 1,2 -o 6 -n 6 -p 0.05 -d -e -w swaths.txt -k openswath -a SpecLib_cons_celltype_alleles_fdr_iRT_openswath.csv SpecLib_cons_celltype_alleles_fdr_iRT.sptxt

The \_openswath.csv file was then converted into a .tsv file and opened in Excel. Reference coordinates for the 11 iRT peptides were confirmed and any remaining decoy sequences were removed. The file was then saved in .txt format and then converted back in .csv format. The OpenSWATH tool ConvertTSVToTraML converted the TSV/CSV file to TraML:

ConvertTSVToTraML -in SpecLib_cons_celltype_alleles_fdr_iRT_openswath.csv -out SpecLib_cons_celltype_alleles_fdr_iRT.TraML

Decoys were appended to the TraML assay library with the OpenSWATH tool OpenSwathDecoyGenerator as described before ([@bib38]; [@bib39]; [@bib43]) in reverse mode with a similarity threshold of 0.05 Da and an identity threshold of 1:

OpenSwathDecoyGenerator -in SpecLib_cons_celltype_alleles_fdr_iRT.TraML -out SpecLib_cons_celltype_alleles_fdr_iRT_decoy.TraML -method shuffle -append -exclude_similar

The library was then uploaded into the iPortal workflow for SWATH data analysis (see below).

DIA mass spectrometry (SWATH-MS) {#s3-8}
--------------------------------

For SWATH-MS data acquisition, the same mass spectrometer and LC-MS/MS setup was operated essentially as described before ([@bib6]; [@bib38]) using 32 windows of 25 Da effective isolation width (with an additional 1 Da overlap on the left side of the window) and with a dwell time of 100 ms to cover the mass range of 400--1200 m/z in 3.3 s. Before each cycle, an MS1 scan was acquired, and then the MS2 scan cycle started (400--425 m/z precursor isolation window for the first scan, 424--450 m/z for the second\... 1,174--1200 m/z for the last scan). The collision energy for each window was set using the collision energy of a 2+ ion centered in the middle of the window with a spread of 15 eV. Four independent international laboratories acquired their own SWATH maps using the settings described above: (1) Antony Purcell, Monash University; (2) Nicola Ternette, University of Oxford; (3) Miguel Marcilla, Spanish National Biotechnology Center; (4) Ruedi Aebersold, ETH-Zurich.

SWATH-MS data analysis {#s3-9}
----------------------

The iPortal workflow was used for data analyses ([@bib29]). The OpenSWATH analysis workflow (OpenSWATHWorkflow) (<http://www.openswath.org>) was implemented in the iPortal workflow. The parameters were selected analogously to the ones described before ([@bib39]): min_rsq: 0.95, min_coverage: 0.6, min_upper_edge_dist: 1, mz_extraction_window: 0.05, rt_extraction_window: 600, extra_rt_extraction_window: 100. pyprophet (<https://pypi.python.org/pypi/pyprophet>) was run on the OpenSwathWorkflow output adjusted to contain the previously described scores (xx_swath_prelim_score, bseries_score, elution_model_fit_score, intensity_score, isotope_correlation_score, isotope_overlap_score, library_corr, library_rmsd, log_sn_score, massdev_score, massdev_score_weighted, norm_rt_score, xcorr_coelution, xcorr_coelution_weighted, xcorr_shape, xcorr_shape_weighted. yseries_score) ([@bib39]). Assay libraries were loaded into Skyline and SWATH traces were analyzed as described previously ([@bib43]). Advanced protocols for analysis of SWATH/DIA data can be downloaded from the website: [http://skyline.maccosslab.org](http://skyline.maccosslab.org/).
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Major datasets {#s5-1}
--------------

The following datasets were generated:

Caron, *et al*, 2015,Mass spectrometry discovery peptidomics data (centroided mzXML and identified peptides in pepXML report) used to generate the HLA-allele specific peptide spectral and assay libraries,<http://proteomecentral.proteomexchange.org>,Publicly available at the ProteomeXchange (Accession no: PXD001872).

Caron, *et al*, 2015,HLA allele-specific peptide spectral libraries (SpectraST format) and assay libraries (CSV, TraML) available for different SWATH-MS data analysis tools,[www.swathatlas.org](http://www.swathatlas.org),Publicly available at the SWATHAtlas. Additional allele-specific spectral libraries (without RT normalization) are available at the PeptideAtlas ([www.peptideatlas.org](http://www.peptideatlas.org)) with the dataset identifier PASS00666.

Caron, *et al*, 2015,Mass spectrometry SWATH-MS data (instrument raw/wiff files and identified peptides in OpenSWATH report),<http://proteomecentral.proteomexchange.org>,Publicly available at the ProteomeXchange (Accession no: PXD001904).
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Thank you for submitting your work entitled "An open-source computational and data resource to analyze digital maps of immunopeptidomes" for peer review at *eLife*. Your submission has been favorably evaluated by Tadatsugu Taniguchi (Senior editor), Arup K Chakraborty (Reviewing editor), and two reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript describes the use of the SWATH-MS methodology for identification and cataloging of HLA peptide repertoires -- viz., \'the Immunopeptidome\'. The manuscript is based on an international collaboration between a few laboratories specializing in HLA immunopeptidome analysis and the laboratory of Dr. Aebersold, who developed the SWATH_MS methodology. In the past, HLA peptides were mostly identified by shotgun proteomics, which is based on the selection of peptides from purified pools of peptides for fragmentation in the mass spectrometer during the LC-MS-MS analysis. The SWATH_MS approach does not select specific peptides for fragmentation, but instead scans repetitively incremental mass windows of about 25 mass units, every time fragmenting all the peptides that are present in each of these mass windows. The method allows fragmenting all the peptides which have the mass divided by charge of the mass region being scanned more than once. The advantage of this approach is the better reproducibility of the data while the disadvantage is the lower sensitivity and the need to establish beforehand a library of spectra of the individual peptides that will be used for identification by the SWATH-MS approach. The use of the peptide preparations and the LC-MS-MS data from the different collaborating labs resulted in successful establishment of a large repository of peptides and their spectra libraries in a format that will be made public and will serve a large community of researchers, enabling better collaborations.

Overall, the work reported in this paper could be a significant resource for the community. But, the following issues need to be addressed to further establish the robustness of the method.

Major points:

1\) In the Introduction, it is suggested that Data-Dependent Acquisition (DDA) used for such analyses of MHC peptidomes results in less reproducible results. This is a well-known fact, but it would be good to show the reproducibility of the results of the same three raw data files when analyzed by the SWATH-MS method and a figure with parallel Venn diagrams indicating how many peptides are identified in each analysis in total, and how many are shared between the runs.

2\) Peptide presentation by HLA C is ignored because it is claimed that they are expressed in low amounts. In Schittenhelm et al. (Tissue Antigens, 2014, 83, 174-179, 2014), an HLA immunopeptidome of HLA C is reported using the C1R cell line. Since the same cell line is used in the present study, ignoring peptide presentation by HLA C seems to be inappropriate. This point needs clarification or inclusion of HLA C in the analysis.

3\) Several search engines (Comet, MS-GF+, X!Tandem) were used to identify peptide sequences from the mass spectrometry data. As can be seen from [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, different engines identify quite different numbers of potential peptides. How should these results be interpreted? Should the union or intersection of these peptide sets be used?

4\) The HLA annotation score, based on the predicted IC~50~ binding affinities from NetMHC server, is used to associate peptides with particular HLA alleles. In a similar server, Immune Epitope Database (IEDB), sometimes the values of experimentally measured and predicted values of IC~50~ can differ by a factor of 10 or more. Using the NetMHC server are the results more robust, thus allowing use of cutoff of value of 3 for the HLA annotation score?

Minor points:

1\) In the first paragraph of Results and Discussion, the comment "no reference computational framework is currently available to facilitate the analysis of such datasets" is not entirely correct, since software tools, such as MaxQuant, Perseus, or X-PRESIDENT can handle HLA-peptidome data without effort (for example: see the second reference cited, [@bib2]).

2\) In the second paragraph of Results and Discussion: "of all identified peptides to their respective HLA allele" is an overstatement, since significant parts of the identified peptides are not annotated to their respective HLA allele.

3\) In the third paragraph of Results and Discussion: "Three synthetic EBV-derived peptides were also used to build the HLA-A02 and -B07 library. How can three peptide by useful for building two libraries? Some clarification is required.

4\) In the fourth paragraph of Results and Discussion: "Class I peptide precursors fall within the range of 400-700 Th" -- this is not correct, since many peptides fall outside this range. We suggest clarifying the percentage of the peptides which fall within this range, and indicating if the loss of these peptides compensate for the additional 17% gained by use of this narrow range. Also, why was the 400-650 mass range selected?

5\) In the subsection headed "Isolation of HLA peptides": We suggest adding the reference by [@bib20] to the references for the method of affinity purification and LC-MS-MS analysis of MHC peptidome.

6\) In the subsection "Generation of HLA allele-specific peptide spectral and assay libraries": Please clarify that the parameters are used for Spectrast, and explain what they mean for readers that do not use Spectrast.

10.7554/eLife.07661.032

Author response

*1) In the Introduction, it is suggested that Data-Dependent Acquisition (DDA) used for such analyses of MHC peptidomes results in less reproducible results. This is a well-known fact, but it would be good to show the reproducibility of the results of the same three raw data files when analyzed by the SWATH-MS method and a figure with parallel Venn diagrams indicating how many peptides are identified in each analysis in total, and how many are shared between the runs*.

This is an important point and we performed the analysis suggested by the reviewers. HLA class I peptides were freshly isolated from JY cells and six technical replicates were consecutively injected in a TripleTOF 5600 -- three datasets were acquired in DDA mode and three datasets were acquired in SWATH/DIA mode. We inserted a new paragraph in the main text of the manuscript to describe the results of this analysis. We also added a new Venn diagram as suggested ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) as well as a new supplementary table ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). In the new version of the manuscript, we now mention (Results and Discussion): "To further establish the robustness of SWATH-MS \[...\] reproducibly identified and quantified from the same digital SWATH maps in the future."

*2) Peptide presentation by HLA C is ignored because it is claimed that they are expressed in low amounts. In Schittenhelm et al. (*[@bib41]*, 83, 174-179, 2014), an HLA immunopeptidome of HLA C is reported using the C1R cell line. Since the same cell line is used in the present study, ignoring peptide presentation by HLA C seems to be inappropriate. This point needs clarification or inclusion of HLA C in the analysis*.

We thank the reviewers for pointing this out. In this study, we focused on HLA-A and -B alleles because of the high reliability of the NetMHC 3.4 predictor for a wide diversity of HLA-A and -B alleles as well as for their high expression levels ([@bib24]; [@bib2]; [@bib49]). We now mention (Results and Discussion): "HLA-A and -B alleles were prioritized due to the high reliability of the NetMHC 3.4 predictor for a broad diversity of HLA-A and -B alleles as well as for their high expression levels ([@bib24]; [@bib2]; [@bib49])."

Please note that a large number of HLA-C alleles will be fully integrated in the next version of the workflow. For instance, the next upgrade will integrate additional epitope prediction algorithms such as NetMHCpan and others from IEDB and will annotate supertype peptides. We also plan to integrate a predictor-independent strategy \[e.g. alignment- and clustering-based approach similar to GibbsCluster and NNalign (Andreatta et al. 2013; Nielson et al. 2009)\] since the HLA annotation score used in this manuscript can only be calculated for well-characterized HLA alleles. Nevertheless, it is correct that C1R cells express a significant number of HLA-C04 peptide ligands. Using C1R cells, Schittenhelm et al. have indeed identified 734 HLA-C04 specific peptides from 10 independent immunoaffinity purifications (Schittenhelm et al., 2014). In our study, 205 HLA-C04 peptide ligands expressed on the surface of C1R cells were identified and are now included in the new version of the manuscript. We now state: "Notably, endogenous HLA-C04 peptides were recently shown to be expressed on the surface of C1R cells ([@bib41]) and were therefore considered in this study. In total, 3,528 HLA-A peptides, 4,208 HLA-B peptides and 205 HLA-C04 peptides were recorded in the spectral libraries". We also state: "Natural class I peptides from three C1R cell lines -- stably expressing HLA-C04 as well as HLA-B27, -B39 or -B40 molecules -- were also isolated using the same procedure."

We updated the total number of unique peptides, alleles and transitions in the main text (Results and Discussion) and an HLA-C04-specific peptide assay library is now available in the SWATH Atlas repository: <https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/GetDIALibs?SBEAMSentrycode=HLASWATH2015>. We also updated [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} and [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}. However, we did not modify the [Figure 2](#fig2){ref-type="fig"} as the focus of this study is on HLA-A and -B alleles and because HLA-C04 peptide ligands would be poorly represented on the heat maps (see [Author response image 1](#fig4){ref-type="fig"}).10.7554/eLife.07661.033Author response image 1.Heat map visualization of HLA-B27 and -C04 peptide ligands isolated from C1R cells.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.033](10.7554/eLife.07661.033)

*3) Several search engines (Comet, MS-GF+, X!Tandem) were used to identify peptide sequences from the mass spectrometry data. As can be seen from* [*Figure 1---figure supplement 2*](#fig1s2){ref-type="fig"}*, different engines identify quite different numbers of potential peptides. How should these results be interpreted? Should the union or intersection of these peptide sets be used*?

Indeed, clarification is needed to explain what are the peptide sets that were used to build the spectral libraries. Combining results of multiple search engines in proteomics has been shown to be beneficial using particular softwares such as MSblender, PepArML and iProphet ([@bib47]). In [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, the venn diagrams were essentially used to roughly compare and visualize the numbers of HLA class I peptides identified by different search engines. However, neither the unions nor the intersections of the venn diagrams were used to build the spectral libraries. Here, the software iProphet was used to combine the search results generated by Comet, MS-GF+ and X!Tandem. In fact, iProphet allows accurate and effective integration of the results from multiple database search engines applied to the same data ([@bib46]). In the revised version of the manuscript, we added a new table in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. The new table shows the numbers of HLA class I peptides obtained from the iProphet combined search results that were used to build the spectral libraries. The new table also shows the sum of peptides identified by the three search engines (Union) as well as the number of overlapping peptides (Intersection) for each Venn diagram/sample. Notably, the numbers of peptides obtained from 'iProphet' and 'Union' are very similar although not identical. In the revised version of the manuscript, we now state (Results and Discussion): "Peptides were identified using multiple open-source database search engines. The search identifications were combined and statistically scored using PeptideProphet and iProphet within the TPP as shown previously ([Figure 1](#fig1){ref-type="fig"}) ([@bib46]; [@bib47])." In addition, the [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} is now entitled: "Combining results of three open-source database search engines in immunopeptidomics using iProphet." Following the addition of the new table, we have decided to remove the Venn diagrams from the search identifications at 1% peptide-level FDR since this information was not essential and a bit redundant.

*4) The HLA annotation score, based on the predicted IC*~*50*~ *binding affinities from NetMHC server, is used to associate peptides with particular HLA alleles. In a similar server, Immune Epitope Database (IEDB), sometimes the values of experimentally measured and predicted values of IC*~*50*~ *can differ by a factor of 10 or more. Using the NetMHC server are the results more robust, thus allowing use of cutoff of value of 3 for the HLA annotation score*?

The results obtained using the NetMHC server are not more robust. In fact, the IEDB uses NetMHC predictors, as well as other methods. Performance, reliability and comparability of IEDB and NetMHC predictors were evaluated in details ([@bib49]; [@bib24]; Peters et al. 2006). Here, a reasonable cutoff value of 3 was selected mainly because \>90% of the identified peptides with an annotation score above 3 have a predicted IC~50~ below 1000nM -- we added this statement in the new version of the manuscript (see Materials and methods, subsection "HLA allele annotation"; and Results and Discussion). Increasing the cutoff value to 5, 50, or 500 would increase the stringency of the annotation process but would reduce significantly the number of peptides in each HLA allele-specific spectral library. In our opinion, this annotation strategy is still in a very early stage and we plan to improve it in the future. In this regard, we now clearly mention in [Supplementary file 1](#SD8-data){ref-type="supplementary-material"} (2. Annotation and Visualization): "The next version of the software tools will integrate statistical bootstrapping analysis to determine the optimal annotation cutoff value for individual datasets. The next upgrade will also integrate additional epitope prediction algorithms from IEDB and will annotate supertype peptides. We also plan to integrate a predictor-independent strategy \[e.g. alignment- and clustering-based approach similar to GibbsCluster and NNalign (Andreatta et al. 2013; Nielson et al. 2009)\] since the HLA annotation score used in this manuscript can only be calculated for well-characterized HLA alleles."

Minor points:

*1) In the first paragraph of Results and Discussion, the comment* "*no reference computational framework is currently available to facilitate the analysis of such datasets\" is not entirely correct, since software tools, such as MaxQuant, Perseus, or X-PRESIDENT can handle HLA-peptidome data without effort (for example: see the second reference cited,* [@bib2]*)*.

We agree with the reviewers. We now state (Results and Discussion, first paragraph): "Large-scale DDA-based identification of immunoaffinity purified HLA class I peptides is supported by several software tools (e.g. MaxQuant, Perseus or X-PRESIDENT) and results in thousands of unclassified peptides of various lengths. Since large HLA peptidomic datasets are generated at an increasing pace, additional computational frameworks facilitating the HLA annotation and storage of such datasets need to be developed."

*2) In the second paragraph of Results and Discussion:* "*of all identified peptides to their respective HLA allele\" is an overstatement, since significant parts of the identified peptides are not annotated to their respective HLA allele*.

We agree with the reviewers that 'all identified peptides' is an overstatement. We now state: 'the majority of the identified peptides'.

*3) In the third paragraph of Results and Discussion:* "*Three synthetic EBV-derived peptides were also used to build the HLA-A02 and -B07 library. How can three peptide by useful for building two libraries? Some clarification is required*.

We agree with the reviewers that some clarification is needed. The idea here was to provide a proof-of-principle that building high-quality assay libraries from synthetic peptides could be useful for the identification of non-self HLA-bound peptides. In the revised version of the manuscript, we now mention "Synthetic EBV-derived peptides known to bind HLA-A02 or -B07 were also used to build the libraries". We also state: "Notably, assays generated from the synthetic EBV-related class I peptides enabled the identification of one EBV-derived HLA-A02 peptide ([Figure 3C](#fig3){ref-type="fig"}), thereby demonstrating that building high-quality assay libraries from synthetic class I peptides of pathogen origin could be useful for the identification of non-self HLA-bound peptides by SWATH-MS."

*4) In the fourth paragraph of Results and Discussion:* "*Class I peptide precursors fall within the range of 400-700 Th\" -- this is not correct, since many peptides fall outside this range. We suggest clarifying the percentage of the peptides which fall within this range, and indicating if the loss of these peptides compensate for the additional 17% gained by use of this narrow range. Also, why was the 400-650 mass range selected*?

We thank the reviewers for this suggestion. To select the 400-650 mass range, we initially used 3,079 manually validated HLA peptide ligands isolated from 15 renal cell carcinomas (RCCs) and we define the range containing 99% of the ligands (see [Author response image 2](#fig5){ref-type="fig"}). Following the publication by Mommen et al. 2014, we re-evaluated the window by opening it up to 350-900m/z and we observed a decrease in unique peptides by ∼25%. The 400-650 mass range is therefore optimal in our hands using an Orbitrap-XL but might be influenced by the dynamic range and scan speeds of individual instruments and sample concentration. Using the Triple-TOF 5600, we observed that 98% of all class I peptide precursors fall within the 400-700 mass range. Thus, we now mention in the revised version of the manuscript: "Most class I peptide precursors (∼98%) fall within the range of 400-700 Th and were divided in 30 SWATH windows of 10 Da width each."10.7554/eLife.07661.034Author response image 2.Selection of the 400-650 mass range. 3,079 manually validated HLA class I ligands from 15 renal cell carcinomas (RCCs) were used to define the mass range containing 99% of the ligands.**DOI:** [http://dx.doi.org/10.7554/eLife.07661.034](10.7554/eLife.07661.034)

*5) In the subsection headed "Isolation of HLA peptides": We suggest adding the reference by* [@bib20] *to the references for the method of affinity purification and LC-MS-MS analysis of MHC peptidome*.

We added the reference (to the subsection "Isolation of HLA peptides").

*6) In the subsection "Generation of HLA allele-specific peptide spectral and assay libraries": Please clarify that the parameters are used for Spectrast, and explain what they mean for readers that do not use Spectrast*.

We clarified that the parameters are used for Spectrast and we now guide the reader to a link where individual parameters are accurately defined. We now state in the revised version of the manuscript: "This section was adapted from [@bib43]. The parameters below were used for Spectrast ([@bib30]). Exact meaning of each parameter can be found in the following link: <http://tools.proteomecenter.org/wiki/index.php?title=Software:SpectraST>."
